Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications |
| |
| Authors: | Rongzhen Wu Hongyu Chen Dr. Ninghui Chang Yuzhi Xu Prof. Dr. Jiao Jiao Prof. Dr. Hailong Zhang |
| |
| Affiliation: | 1. Department of Chemistry, Southern University of Science and Technology of China, Shenzhen, 518055 P. R. China;2. Department of Biology, Southern University of Science and Technology of China, Shenzhen, 518055 P. R. China;3. Department of Chemistry, School of Science, Northwestern Polytechnical University, Xi'an, 710072 P. R. China;4. School of Materials Science and Engineering, South China University of Technology, Guangzhou, 510006 P. R. China;5. Department of Chemistry, School of Science, Xi'an Key Laboratory of Sustainable Energy Materials Chemistry, Xi'an Jiaotong University, Xi'an, 710049 P. R. China;6. School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061 P. R. China |
| |
| Abstract: | Bryostatins are a class of naturally occurring macrocyclic lactones with a unique fast developing portfolio of clinical applications, including treatment of AIDS, Alzheimer's disease, and cancer. This comprehensive account summarizes the recent progress (2014–present) in the development of bryostatins, including their total synthesis and biomedical applications. An emphasis is placed on the discussion of bryostatin 1 , the most-studied analogue to date. This review highlights the synthetic and biological challenges of bryostatins and provides an outlook on their future development. |
| |
| Keywords: | antitumor agents bioactivity bryostatins drug discovery total synthesis |
|
|
